|
| |
Arena PharmaceuticalsLINE provides logistics solutions that enable companies to move goods around the world in the simplest and most efficient way. Our systems offer every participant in the supply chain access to new levels of efficiency and the opportunity to provide better service at lower cost.
We enable the logistics and transportation market to optimize its processes while retaining control of its own customer and supplier relationships and systems. LINE creates tangible and immediate value for our customers.
| Contact Details: |
| 6166 Nancy Ridge Drive |
| San Diego |
| |
| 92121 |
| United States of America |
| Tel: | 858 453 7200 |
| Fax: | 858.453.7210 |
| Email: | invest@arenapharm.com |
| WWW: | www.arenapharm.com/
|
| |
Recent Publications by Arena Pharmaceuticals: |  |
N-Oleoyldopamine Enhances Glucose Homeostasis through the Activation of GPR119.
G protein-coupled receptor 119 (GPR119) is largely restricted to... | 11th November, 2009
| Arena Pharmaceuticals, San Diego, California 92121.
| Mol Endocrinol. 2009 Nov 9.
DOI Direct Link |
Nelotanserin, a Novel Selective Human 5-Hydroxytryptamine2A Inverse Agonist for the Treatment of Insomnia.
5-hydroxytryptamine (5-HT)(2A) receptor inverse agonists are promising... | 21st October, 2009
| 1 Arena Pharmaceuticals Inc.;
| J Pharmacol Exp Ther. 2009 Oct 19.
DOI Direct Link |
Design and evaluation of novel biphenyl sulfonamide derivatives with potent histamine H(3) receptor inverse agonist activity.
Antagonism of the histamine-H(3) receptor is one tactic being explored to... | 15th October, 2009
| Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San Diego, California
| J Med Chem. 2009 Sep 24;52(18):5603-11.
DOI Direct Link |
APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)ben zamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology.
We have evaluated the receptor pharmacology, antiplatelet activity, and... | 14th October, 2009
| Arena Pharmaceuticals, Inc., San Diego, CA 92121, USA.
| J Pharmacol Exp Ther. 2009 Oct;331(1):96-103. Epub 2009 Jul 23.
DOI Direct Link |
GPR119 agonists for the treatment of type 2 diabetes.
BACKGROUND: Diabetes is a chronic disease that occurs when the pancreas... | 29th September, 2009
| Departments of Medicinal Chemistry & Metabolic Disorders, Arena
| Expert Opin Ther Pat. 2009 Oct;19(10):1339-59.
DOI Direct Link |
→View more Arena Pharmaceuticals research publications. |
Press Releases on Arena Pharmaceuticals:
|
 |
| Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009 |
4th November, 2009 |
Arena Pharmaceuticals, Inc. |
SAN DIEGO, Nov. 4, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report third quarter 2009 financial results after the NASDAQ Global Market closes
|
| New Data From Arena Pharmaceuticals' Pivotal BLOSSOM Trial of Lorcaserin Demonstrate Improvements in Patients' Body Composition, Cardiovascular Risk Factors and Quality of Life |
27th October, 2009 |
Arena Pharmaceuticals, Inc. |
WASHINGTON, Oct. 27, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported today data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for
|
| Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation |
25th October, 2009 |
Arena Pharmaceuticals, Inc. |
WASHINGTON, Oct. 25, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported that data from the pivotal BLOOM (Behavioral modification and Lorcaserin for Overweight and
|
| Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences |
22nd October, 2009 |
Arena Pharmaceuticals, Inc. |
SAN DIEGO, Oct. 22, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to provide an overview of the company at two upcoming
|
| Arena Pharmaceuticals' Lorcaserin to be Featured in Multiple Presentations at Obesity 2009 |
12th October, 2009 |
Arena Pharmaceuticals, Inc. |
SAN DIEGO, Oct. 12, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that lorcaserin will be featured in multiple presentations at Obesity 2009, the 27th
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 940 times since April 2007, the link to the organisation's website has been followed 136 times Recent Search Terms used to find this page: arena pharm nancy ridge dr san diego | Arena Pharmaceuticals logo | europe arena pharmaceutic | Arena Pharmaceuticals 6166 Nancy Ridge San Diego CA 92121 | arena medicinal chemistry | arena pharma May 2009 | arenapharm san diego news | arena phar. at san diego | arena pharm april 23 2009 | arena pharmaceuticals san diego april 2009 | . Search for more companies in San Diego Search for more companies in This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Arena Pharmaceuticals |
